Boehringer Ingelheim logo

Boehringer Ingelheim

Crunchbase
Pitchbook
Crunchbase

Deals on record

5

Common Fundraising Type

Series B

Refoxy Pharmaceuticals is a biotech company developing small molecule activators of the FOXO3 transcription factor to treat age-related diseases, with an initial focus on idiopathic pulmonary fibrosis.

Seed
$9.6M
12/04/2024
Article

Aignostics is a Berlin-based AI company that transforms multi-modal pathology data into insights for biopharmaceutical clients.

Series B
$34M
10/29/2024
Article

Glox Therapeutics develops precision antibiotics targeting drug-resistant bacteria, with a focus on creating high-potency bacteriocins to selectively target and kill antibiotic-resistant Gram-negative pathogens while preserving the patient's microbiome.

Seed
$5.3M
11/14/2023
Article
Actym Therapeutics logo
Actym Therapeutics

Cancer treatment

Actym Therapeutics develops a new drug modality using genetically modified bacteria to initiate a selective immune response within the tumor microenvironment for treating solid tumors.

Series A
$25.5M
10/18/2023
Article
Otto logo
Otto

AI-driven

Hill's Pet Nutrition logo
Mercury Fund logo
Boehringer Ingelheim logo

Otto is developing an AI-driven travel assistant tailored for small businesses and startups, offering personalized travel planning and booking services.

Series B
$43M
08/31/2023
Article